PSMA PET is highly robust in identifying prostate cancer lesions which are otherwise deemed unremarkable.

68Ga prostate specific membrane antigen (PSMA) positron emission tomography (PET) has high utility in the detection of suspicious lesions in biochemically recurrent prostate cancer. This is according to study results presented at the Radiological Society of North America (RSNA) 2021 Annual Meeting.

“PSMA PET is a more robust modality for biochemical recurrence with the potential of identifying small lesions which would otherwise be dismissed on MRI alone,” the authors wrote. “We recommend the use of 68Ga PSMA PET/MR for biochemical recurrent prostate cancer with potential to be the new standard of care for this indication.”

Please visit Diagnostic Imaging to read more